Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: capecitabine|DRUG: cyclophosphamide|DRUG: lapatinib ditosylate|BIOLOGICAL: trastuzumab|OTHER: laboratory biomarker analysis
Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)